rifampin and Facial-Dermatoses

We report a case of Mycobacterium marinum facial sporotrichoid infection in an otherwise healthy 2-year-old child, probably acquired through contact with pets in an aquarium. The M. marinum isolate was susceptible to clarithromycin, and the child was successfully treated with oral antibiotic therapy. This unusual case emphasizes the importance of a thorough history in the evaluation of a patient with chronic sporotrichoid skin lesions.

Topics: Administration, Oral; Anti-Bacterial Agents; Child, Preschool; Chronic Disease; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Facial Dermatoses; Humans; Male; Mycobacterium Infections, Nontuberculous; Rifampin; Sporotrichosis

Topics: Adolescent; Angioedema; Biopsy; Chronic Disease; Clofazimine; Dapsone; Developing Countries; Diagnosis, Differential; Drug Therapy, Combination; Facial Dermatoses; Follow-Up Studies; Humans; India; Leprosy, Multibacillary; Male; Rifampin; Sinusitis; Skin

Topics: Adult; Alopecia; Clofazimine; Dapsone; Eyebrows; Facial Dermatoses; Humans; Leprostatic Agents; Leprosy, Multibacillary; Male; Rifampin

Topics: Antitubercular Agents; Bronchitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; CD4-CD8 Ratio; Diagnosis, Differential; Diagnostic Errors; Drug Therapy, Combination; Ethambutol; Facial Dermatoses; Female; Humans; Isoniazid; Middle Aged; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Sarcoidosis; Sputum; Tuberculosis, Cutaneous; Tuberculosis, Pulmonary

A small percentage of patients with tuberculosis present with cutaneous findings, which may be difficult to diagnose. We present a patient diagnosed with a rare, non-scarring form of cutaneous tuberculosis (CTB), classically termed as lupus vulgaris erythematoides.

Topics: Adrenal Cortex Hormones; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Biopsy; Calcineurin Inhibitors; Dermis; Diagnostic Errors; Drug Therapy, Combination; Eczema; Erythema; Facial Dermatoses; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Isoniazid; Lupus Vulgaris; Mycobacterium tuberculosis; Necrosis; Nose Diseases; Pyrazinamide; Rifampin

Buruli ulcer (BU) denotes a cutaneous infection by Mycobacterium ulcerans endemic in certain tropical and subtropical regions. Treatment may be either medical and surgical or else purely medical for early lesions. The literature contains reports of several cases of transient aggravation of BU following initiation of medical treatment. We report a case observed in the Ivory Coast, one of the areas with the highest prevalence of BU worldwide. The distinguishing features of our case are the early onset of this paradoxical reaction and the multiple cephalic site of lesions.. A 4-year-old child with no prior medical history was referred for two painless ulcerative cutaneous nodules. Incubation of samples from the edges of these lesions revealed the presence of acid-alcohol resistant bacilli (AARB), which were shown by PCR to be M. ulcerans, the causative agent in BU. Treatment consisted of levofloxacin (100mg/d) and rifampicin (150mg/d) for 8weeks. After 7days of medical treatment, seven painless nodules appeared on the patient's scalp. Further PCR for these lesions confirmed the presence of M. ulcerans. The same medical therapy was maintained and after 54days of treatment, all lesions had been healed.. The originality of this case rests on two features: the bifocal aspect of the lesions, which is uncommon, and the early development of cephalic predominance that occurred after the start of drug treatment. While cases of lesions secondary to initiation of medical therapy have already been described, such lesions generally occurred after at least 2months of treatment and did not involve the head.

Topics: Anti-Bacterial Agents; Buruli Ulcer; Child, Preschool; Chin; Cicatrix; Cote d'Ivoire; Drug Therapy, Combination; Endemic Diseases; Facial Dermatoses; Female; Humans; Leg; Levofloxacin; Mycobacterium ulcerans; Ofloxacin; Rifampin; Scalp Dermatoses; Time Factors

Topics: Adult; Africa, Northern; Antitubercular Agents; Emigrants and Immigrants; Facial Dermatoses; Female; Humans; Isoniazid; Lupus Vulgaris; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Skin; Spain

Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B-Lymphocytes; CD3 Complex; Clofazimine; Dapsone; Drug Therapy, Combination; Emergencies; Face; Facial Dermatoses; Humans; Leprostatic Agents; Leprosy, Borderline; Leprosy, Tuberculoid; Male; Prednisone; Receptors, Cell Surface; Rifampin; T-Lymphocytes; Treatment Outcome

Leprosy is a chronic, infectious, systemic disease caused by Mycobacterium leprae and is classified as paucibacillary and multibacillary types. It is contagious and has an insidious onset. Clinical presentation is characterised by hypopigmented skin lesions with reduced sensation. Presence of acid-fast bacilli in tissue specimens is regarded as a gold standard for diagnosis. Treatment is based on multi-drug regimens. We report a case of borderline tuberculoid leprosy in a 31-year-old woman.

Topics: Adult; Cellulitis; Dapsone; Diagnosis, Differential; Facial Dermatoses; Female; Glucocorticoids; Humans; Leprostatic Agents; Leprosy, Borderline; Leprosy, Tuberculoid; Mycobacterium leprae; Prednisolone; Rifampin

Topics: Brazil; Dapsone; Delayed Diagnosis; Facial Dermatoses; Female; Foot Dermatoses; Hand Dermatoses; Humans; Hypesthesia; Immunity, Cellular; Leprosy, Tuberculoid; Occupational Exposure; Prednisone; Pregnancy; Pregnancy Complications, Infectious; Rifampin; Spain

Topics: Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Facial Dermatoses; Female; Granuloma; Humans; Isoniazid; Mycobacterium Infections; Pyrazinamide; Rifampin; Skin Diseases, Bacterial

Leprosy is now considered in Western Europe as a strictly imported disease. A case of presumed locally acquired diffuse lepromatous leprosy was observed in a native-Portuguese woman living in France who developed an acute febrile presentation with extensive cutaneous signs.

Topics: Biopsy, Needle; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Facial Dermatoses; Female; Fever; Follow-Up Studies; France; Humans; Immunohistochemistry; Leg Dermatoses; Leprosy, Lepromatous; Middle Aged; Rifampin; Risk Assessment; Severity of Illness Index; Treatment Outcome

Topics: Adult; Antigens, Bacterial; Dapsone; Facial Dermatoses; Fever; Humans; Leprostatic Agents; Leprosy, Borderline; Male; Mycobacterium leprae; Peripheral Nervous System Diseases; Philippines; Prednisone; Rifampin; Uveitis

The incidence of cutaneous bacterial infection after carbon dioxide (CO2 laser resurfacing is increasing. Patients with staphylococcal colonization of their anterior nares may be at greater risk for postoperative cutaneous colonization and/or infection, which can potentially cause scarring.. We present a case report of methicillin-resistant Staphylococcus aureus secondary infection of the skin after CO2 laser resurfacing. We discuss the possible etiologies of this patient's infection, her postoperative management, and preoperative suggestions for possibly preventing infection.. A 49-year-old woman was treated with CO2 laser resurfacing for moderate actinic damage and facial rhytides. She developed a cutaneous infection with methicillin-resistant S. aureus, which caused diffuse linear scarring on her cheeks and upper lip.. The patient was successfully treated with oral minocycline, rifampin, and topical mupiricin ointment to her cutaneous erosions.. We propose that it would be helpful for patients undergoing CO2 laser resurfacing to have their nares cultured to see if they are staphylococcal carriers. If a patient is found to be a carrier, mupiricin ointment can be used preoperatively treat to the nares, to help decrease the risk of infection of the skin from this potential source.

Topics: Dermatologic Surgical Procedures; Drug Therapy, Combination; Facial Dermatoses; Female; Humans; Laser Therapy; Methicillin Resistance; Middle Aged; Minocycline; Mupirocin; Rifampin; Skin Aging; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Surgery, Plastic; Surgical Wound Infection

This study reports the clinical profile and therapeutic response of seventy-two mono-lesions leprosy cases. These 72 cases were among 578 paucibacillary (PB) cases classified according to WHO (1982) and were followed-up on multidrug therapy (MDT). Of these 72 mono-lesion cases, 46 (64%) were tuberculoid (TT) cases, 24 (33%) were Indeterminate (Ind) cases and 2 (3%) were of borderline tuberculoid (BT) types. While 37.5% of these cases presented as macular patches, the remaining 62.5% had raised erythematous lesions. In majority of cases (94%), the lesions were present on the exposed parts like legs and feet, arms and hands, face, whereas only 6% presented on covered areas of trunk and buttocks. These cases were treated with dapsone 100 mg daily for 12 months and rifampicin 600 mg once a month for 6 months. After 6 months of MDT, lesions in 81% of the patients regressed clinically and by one year of therapy 96% of cases had regressed. Treatment was stopped in all cases by one year of therapy. There were no relapse or late reaction in the 5 years of post treatment follow-up. The response of mono-lesion PB cases was better than the multi-lesions PB cases at 6 months and during the post treatment follow-up period.

Topics: Adolescent; Adult; Arm; Dapsone; Drug Therapy, Combination; Facial Dermatoses; Follow-Up Studies; Humans; Leg Dermatoses; Leprosy, Borderline; Leprosy, Tuberculoid; Middle Aged; Recurrence; Remission Induction; Rifampin